Nonacidic Farnesoid X Receptor Modulators

Journal of Medicinal Chemistry

Volumn 60, Issue 16, 2017, Pages 7199-7205

  Flesch, Daniel ^a   Cheung, Sun Yee ^a   Schmidt, Jurema ^a   Gabler, Matthias ^a   Heitel, Pascal ^a   Kramer, Jan ^a   Kaiser, Astrid ^a   Hartmann, Markus ^a   Lindner, Mara ^c   Lüddens Dämgen, Kerstin ^b   Heering, Jan ^c   Lamers, Christina ^a   Lüddens, Hartmut ^b   Wurglics, Mario ^a   Proschak, Ewgenij ^a   Schubert Zsilavecz, Manfred ^a   Merk, Daniel ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESOID X RECEPTOR; FARNESOID X RECEPTOR MODULATOR; HORMONE RECEPTOR AFFECTING AGENT; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; 6-CHLORO-2-(4-CHLOROPYRIDIN-2-YL)-N-(4-METHOXYBENZYL)IMIDAZO(1,2-A)PYRIDIN-3-AMINE; ABC TRANSPORTER; ABCB11 PROTEIN, HUMAN; CARRIER PROTEIN; CELL RECEPTOR; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYP7A1 PROTEIN, HUMAN; FARNESOID X-ACTIVATED RECEPTOR; IMIDAZOLE DERIVATIVE; NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 2; ORGANIC SOLUTE TRANSPORTER ALPHA, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRIDINE DERIVATIVE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; ZOLPIDEM;

ARTICLE; DRUG SELECTIVITY; EC50; LIGAND BINDING; MOLECULAR DOCKING; PHARMACOPHORE; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG STABILITY; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HEP-G2 CELL LINE; HUMAN; MALE; METABOLISM; SPRAGUE DAWLEY RAT; SYNTHESIS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; DRUG STABILITY; HEK293 CELLS; HELA CELLS; HEP G2 CELLS; HUMANS; IMIDAZOLES; MALE; MEMBRANE TRANSPORT PROTEINS; MOLECULAR DOCKING SIMULATION; PPAR ALPHA; PYRIDINES; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85028599832     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b00903     Document Type: Article

References (34)

1. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Palladino, G.; Cipriani, S. Targetting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment Curr. Med. Chem. 2010, 17, 139-159 10.2174/092986710790112666
2. Halilbasic, E.; Claudel, T.; Trauner, M. Bile Acid Transporters and Regulatory Nuclear Receptors in the Liver and beyond J. Hepatol. 2013, 58, 155-168 10.1016/j.jhep.2012.08.002
3. Modica, S.; Gadaleta, R. M.; Moschetta, A. Deciphering the Nuclear Bile Acid Receptor FXR Paradigm Nucl. Recept. Signaling 2010, 8, e005 10.1621/nrs.08005
4. Neuschwander-Tetri, B. A.; Loomba, R.; Sanyal, A. J.; Lavine, J. E.; Van Natta, M. L.; Abdelmalek, M. F.; Chalasani, N.; Dasarathy, S.; Diehl, A. M.; Hameed, B.; Kowdley, K. V.; McCullough, A.; Terrault, N.; Clark, J. M.; Tonascia, J.; Brunt, E. M.; Kleiner, D. E.; Doo, E. Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial Lancet 2015, 385, 956-965 10.1016/S0140-6736(14)61933-4
5. Mudaliar, S.; Henry, R. R.; Sanyal, A. J.; Morrow, L.; Marschall, H. U.; Kipnes, M.; Adorini, L.; Sciacca, C. I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Gastroenterology 2013, 145, 574-582 10.1053/j.gastro.2013.05.042
6. Hollman, D. a a; Milona, A.; Van Erpecum, K. J.; Van Mil, S. W. C. Anti-Inflammatory and Metabolic Actions of FXR: Insights into Molecular Mechanisms Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2012, 1821, 1443-1452 10.1016/j.bbalip.2012.07.004
7. Lamers, C.; Schubert-Zsilavecz, M.; Merk, D. Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists Curr. Top. Med. Chem. 2014, 14, 2188-2205 10.2174/1568026614666141112103516
8. Wang, Y.-D.; Chen, W.-D.; Wang, M.; Yu, D.; Forman, B. M.; Huang, W. Farnesoid X Receptor Antagonizes Nuclear Factor kappaB in Hepatic Inflammatory Response Hepatology 2008, 48, 1632-1643 10.1002/hep.22519
9. Ho, P. P.; Steinman, L. Obeticholic Acid, a Synthetic Bile Acid Agonist of the Farnesoid X Receptor, Attenuates Experimental Autoimmune Encephalomyelitis Proc. Natl. Acad. Sci. U. S. A. 2016, 113, 1600-1605 10.1073/pnas.1524890113
10. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal Chemistry of Farnesoid X Receptor Ligands: From Agonists and Antagonists to Modulators Future Med. Chem. 2012, 4, 1015-1036 10.4155/fmc.12.47
11. Xu, Y. Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases J. Med. Chem. 2016, 59, 6553-6579 10.1021/acs.jmedchem.5b00342
12. Pellicciari, R.; Passeri, D.; De Franco, F.; Mostarda, S.; Filipponi, P.; Colliva, C.; Gadaleta, R. M.; Franco, P.; Carotti, A.; Macchiarulo, A.; Roda, A.; Moschetta, A.; Gioiello, A. Discovery of 3α,7α,11β-Trihydroxy-6α-Ethyl-5β-Cholan-24-Oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders J. Med. Chem. 2016, 59, 9201-9214 10.1021/acs.jmedchem.6b01126
13. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P. R.; Morelli, A.; Parks, D. J.; Willson, T. M. 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity J. Med. Chem. 2002, 45, 3569-3572 10.1021/jm025529g
14. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, a. M.; Chandra, G.; Plunket, K. D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. a.; Willson, T. M. Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR J. Med. Chem. 2000, 43, 2971-2974 10.1021/jm0002127
15. Howarth, D. L.; Law, S. H. W.; Law, J. M.; Mondon, J. A.; Kullman, S. W.; Hinton, D. E. Exposure to the Synthetic FXR Agonist GW4064 Causes Alterations in Gene Expression and Sublethal Hepatotoxicity in Eleutheroembryo Medaka (Oryzias Latipes) Toxicol. Appl. Pharmacol. 2010, 243, 111-121 10.1016/j.taap.2009.11.022
16. Chiang, P.; Thompson, D. C.; Ghosh, S.; Heitmeier, M. R. A Formulation-enabled Preclinical Efficacy Assessment of a Farnesoid X Receptor Agonist, GW4064, in Hamsters and Cynomolgus Monkeys J. Pharm. Sci. 2011, 100, 4722-4733 10.1002/jps.22664
17. Akwabi-Ameyaw, A.; Bass, J. Y.; Caldwell, R. D.; Caravella, J. a.; Chen, L.; Creech, K. L.; Deaton, D. N.; Jones, S. a.; Kaldor, I.; Liu, Y.; Madauss, K. P.; Marr, H. B.; McFadyen, R. B.; Miller, A. B.; Iii, F. N.; Parks, D. J.; Spearing, P. K.; Todd, D.; Williams, S. P.; Wisely, G. B. Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Naphthoic Acid-Based Analogs of GW 4064 Bioorg. Med. Chem. Lett. 2008, 18, 4339-4343 10.1016/j.bmcl.2008.06.073
18. Flatt, B.; Martin, R.; Wang, T. L.; Mahaney, P.; Murphy, B.; Gu, X. H.; Foster, P.; Li, J.; Pircher, P.; Petrowski, M.; Schulman, I.; Westin, S.; Wrobel, J.; Yan, G.; Bischoff, E.; Daige, C.; Mohan, R. Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR) J. Med. Chem. 2009, 52, 904-907 10.1021/jm8014124
19. Singh, N.; Yadav, M.; Singh, A. K.; Kumar, H.; Dwivedi, S. K. D.; Mishra, J. S.; Gurjar, A.; Manhas, A.; Chandra, S.; Yadav, P. N.; Jagavelu, K.; Siddiqi, M. I.; Trivedi, A. K.; Chattopadhyay, N.; Sanyal, S. Synthetic FXR Agonist GW4064 Is a Modulator of Multiple G Protein-Coupled Receptors Mol. Endocrinol. 2014, 28, 659-673 10.1210/me.2013-1353
20. Sepe, V.; Festa, C.; Renga, B.; Carino, A.; Cipriani, S.; Finamore, C.; Masullo, D.; del Gaudio, F.; Monti, M. C.; Fiorucci, S.; Zampella, A. Insights on FXR Selective Modulation. Speculation on Bile Acid Chemical Space in the Discovery of Potent and Selective Agonists Sci. Rep. 2016, 6, 19008 10.1038/srep19008
21. Festa, C.; Renga, B.; D'Amore, C.; Sepe, V.; Finamore, C.; De Marino, S.; Carino, A.; Cipriani, S.; Monti, M. C.; Zampella, A.; Fiorucci, S. Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands J. Med. Chem. 2014, 57, 8477-8495 10.1021/jm501273r
22. Gioiello, A.; Macchiarulo, A.; Carotti, A.; Filipponi, P.; Costantino, G.; Rizzo, G.; Adorini, L.; Pellicciari, R. Extending SAR of Bile Acids as FXR Ligands: Discovery of 23-N-(Carbocinnamyloxy)-3α,7α-Dihydroxy-6α-Ethyl-24-nor-5β-Cholan-23-Amine Bioorg. Med. Chem. 2011, 19, 2650-2658 10.1016/j.bmc.2011.03.004
23. Richter, H. G. F.; Benson, G. M.; Bleicher, K. H.; Blum, D.; Chaput, E.; Clemann, N.; Feng, S.; Gardes, C.; Grether, U.; Hartman, P.; Kuhn, B.; Martin, R. E.; Plancher, J. M.; Rudolph, M. G.; Schuler, F.; Taylor, S. Optimization of a Novel Class of Benzimidazole-Based Farnesoid X Receptor (FXR) Agonists to Improve Physicochemical and ADME Properties Bioorg. Med. Chem. Lett. 2011, 21, 1134-1140 10.1016/j.bmcl.2010.12.123
24. Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET; Smith, D. A., Ed.; RSC Drug Discovery; Royal Society of Chemistry: Cambridge, U.K., 2010.
25. Achenbach, J.; Gabler, M.; Steri, R.; Schubert-Zsilavecz, M.; Proschak, E. Identification of Novel Farnesoid X Receptor Modulators Using a Combined Ligand- and Structure-Based Virtual Screening MedChemComm 2013, 4, 920 10.1039/c3md00049d
26. Groebke, K.; Weber, L.; Mehlin, F. Synthesis of Imidazo[1,2-a] Annulated Pyridines, Pyrazines and Pyrimidines by a Novel Three-Component Condensation Synlett 1998, 1998, 661-663 10.1055/s-1998-1721
27. McKeown, M. R.; Shaw, D. L.; Fu, H.; Liu, S.; Xu, X.; Marineau, J. J.; Huang, Y.; Zhang, X.; Buckley, D. L.; Kadam, A.; Zhang, Z.; Blacklow, S. C.; Qi, J.; Zhang, W.; Bradner, J. E. Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors J. Med. Chem. 2014, 57, 9019-9027 10.1021/jm501120z
28. Flesch, D.; Schubert-Zsilavecz, M. Synthesis of imidazo[1,2-a]pyridines in a Sequential One-Pot Groebke-Blackburn Modification Using 2-Aminopyridines, Aldehydes and Amines Pharmazie 2015, 70, 507-510
29. Merk, D.; Lamers, C.; Ahmad, K.; Gomez, R. C.; Schneider, G.; Steinhilber, D.; Schubert-zsilavecz, M. Extending the Structure-Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist J. Med. Chem. 2014, 57, 8035-8055 10.1021/jm500937v
30. Costantino, G.; Entrena-Guadix, A.; Macchiarulo, A.; Gioiello, A.; Pellicciari, R. Molecular Dynamics Simulation of the Ligand Binding Domain of Farnesoid X Receptor. Insights into Helix-12 Stability and Coactivator Peptide Stabilization in Response to Agonist Binding J. Med. Chem. 2005, 48, 3251-3259 10.1021/jm049182o
31. Beno, B. R.; Yeung, K.-S.; Bartberger, M. D.; Pennington, L. D.; Meanwell, N. A. A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design J. Med. Chem. 2015, 58, 4383-4438 10.1021/jm501853m
32. Schmidt, J.; Klingler, F.-M.; Proschak, E.; Steinhilber, D.; Schubert-Zsilavecz, M.; Merk, D. NSAIDs Ibuprofen, Indometacin, and Diclofenac Do Not Interact with Farnesoid X Receptor Sci. Rep. 2015, 5, 14782 10.1038/srep14782
33. Gioiello, A.; Cerra, B.; Mostarda, S.; Guercini, C.; Pellicciari, R.; Macchiarulo, A. Bile Acid Derivatives as Ligands of the Farnesoid X Receptor: Molecular Determinants for Bile Acid Binding and Receptor Modulation Curr. Top. Med. Chem. 2014, 14, 2159-2174 10.2174/1568026614666141112100208
34. Proschak, E.; Heitel, P.; Kalinowsky, L.; Merk, D. Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery J. Med. Chem. 2017, 60, 5235-5266 10.1021/acs.jmedchem.6b01287